What is the recommended dose of Ferinject (ferric carboxymaltose) for treating iron deficiency anemia in adults and adolescents over 14 years?

Ferinject (Ferric Carboxymaltose) Dosing

For adults and adolescents over 14 years with iron deficiency anemia, administer Ferinject 750 mg intravenously in two doses separated by at least 7 days for a total cumulative dose of 1,500 mg per course in patients weighing ≥50 kg, or 15 mg/kg body weight in two doses for patients <50 kg. 1

Standard Dosing for Iron Deficiency Anemia

Patients Weighing ≥50 kg

• Two doses of 750 mg each, separated by at least 7 days (total 1,500 mg per course) 1
• Alternative single-dose regimen: 15 mg/kg body weight up to maximum 1,000 mg as a single dose per course 1
• In Europe, 1,000 mg is routinely administered per dose, whereas US labeling recommends 750 mg 2

Patients Weighing <50 kg

• 15 mg/kg body weight in two doses separated by at least 7 days 1

Dosing for Iron Deficiency in Heart Failure Patients

For patients with heart failure and New York Heart Association class II/III, dosing is weight and hemoglobin-based 1:

Patients <70 kg

• Hemoglobin <10 g/dL: 1,000 mg on Day 1, then 500 mg at Week 6 1
• Hemoglobin 10-14 g/dL: 1,000 mg on Day 1 only 1
• Hemoglobin >14 to <15 g/dL: 500 mg on Day 1 only 1

Patients ≥70 kg

• Hemoglobin <10 g/dL: 1,000 mg on Day 1, then 1,000 mg at Week 6 1
• Hemoglobin 10-14 g/dL: 1,000 mg on Day 1, then 500 mg at Week 6 1
• Hemoglobin >14 to <15 g/dL: 500 mg on Day 1 only 1

Maintenance Dosing for Heart Failure

• Administer 500 mg at 12,24, and 36 weeks if serum ferritin <100 ng/mL or ferritin 100-300 ng/mL with transferrin saturation <20% 1
• No data available to guide dosing beyond 36 weeks or with hemoglobin ≥15 g/dL 1

Administration Methods

Undiluted Slow IV Push

• Administer 500 or 750 mg at approximately 100 mg (2 mL) per minute 1
• For 1,000 mg doses, administer over 15 minutes 1

IV Infusion

• Dilute up to 1,000 mg in no more than 250 mL of 0.9% sodium chloride 1
• Concentration must not be less than 2 mg iron/mL 1
• Infuse over at least 15 minutes 1, 3
• Solution is stable for 72 hours at room temperature when properly diluted 1

The European Society of Cardiology recommends dilution in 100 mL of normal saline and infusion over 20-30 minutes 3, though FDA labeling permits larger volumes and shorter infusion times 1.

Monitoring Requirements

Immediate Post-Administration

• Observe patients for at least 30 minutes following each injection for adverse effects 3
• Resuscitation equipment must be immediately available 3

Follow-Up Laboratory Testing

• Recheck complete blood count and iron parameters (ferritin, transferrin saturation) 4-8 weeks after the last infusion 3
• Do not evaluate iron parameters within 4 weeks of administration, as circulating iron interferes with assays 3
• Hemoglobin should increase within 1-2 weeks and by 1-2 g/dL within 4-8 weeks 3
• For heart failure patients, re-evaluate iron status at 3 months 3

Repeat Treatment Monitoring

• Check serum phosphate levels in patients requiring repeat treatment within 3 months 1
• Treat hypophosphatemia as medically indicated 1

Critical Safety Considerations

Contraindications

• Hypersensitivity to ferric carboxymaltose or excipients 3
• Known serious hypersensitivity to other parenteral iron products 3
• Anemia not attributed to iron deficiency 3
• Evidence of iron overload 3
• Do not administer if hemoglobin >15 g/dL 3

Important Cautions

• Avoid extravasation—brown discoloration may be long-lasting 1
• Monitor for extravasation and discontinue at that site if it occurs 1
• Use with caution in patients with acute or chronic infection (stop treatment in bacteremia) 3
• Use with caution in patients with known drug allergies, especially severe asthma, eczema, or atopic allergies 3
• Ferric carboxymaltose has higher rates of hypophosphatemia (58%) compared to other IV iron formulations 3
• Most hypophosphatemia is asymptomatic and resolves without intervention 3
• Avoid in patients requiring frequent repeat infusions due to hypophosphatemia risk 3

Clinical Advantages

Ferric carboxymaltose offers significant practical benefits over older formulations 3:

• Can deliver up to 1,000 mg iron in a single 15-minute infusion 3, 4
• Requires fewer clinic visits than iron sucrose (1-2 visits vs. 4-7 visits) 3
• Lower risk of anaphylaxis compared to iron dextran 3
• First IV iron formulation associated with fewer cardiovascular events and hospitalizations in heart failure patients 3